Bayer has announced that it has extended its research partnership with the Broad Institute by five years, bringing to fifteen years a collaboration that began in 2013 in the field of human genomics applied to cardiovascular disease.

This expanded agreement aims to strengthen the identification of precision therapeutic targets in cardiology and accelerate the validation of discoveries through a human cardiomyocyte platform.

The joint research focuses in particular on dilated cardiomyopathy (DCM), a condition characterized by dilation of the heart chambers leading to heart failure.

The collaboration has already led to several publications and the entry into Phase I, in May 2025, of a selective GIRK4 inhibitor for the potential treatment of atrial fibrillation.

Bayer says the partnership is part of its strategy to develop innovative therapies in cardiovascular health, an area of high medical need.


Copyright (c) 2025 CercleFinance.com. All rights reserved.